Abstract
Crohns disease (CD) is a chronic inflammatory disorder which may involve any part of gastrointestinal tract. Chronic inflammation is primarily due to an immunological imbalance between pro- and anti-inflammatory cytokines, and with a defective apoptosis of lamina propria T cells. Amongst the pro-inflammatory cytokines tumor necrosis factor-α (TNF-α) seems to play a central role in pathogenesis of CD. Over the last years, increasing knowledge on the pathogenesis of CD together with progresses in bio-technology have led to the development of a number of biological agents targeting specific molecules involved in gut inflammation, most importantly TNF-α and its receptors. The aim of this paper is to critically review the rationale and state-of-the art for the use TNF-α inhibitors in the treatment of CD.
Keywords: Infliximab, TNF receptors, Lipopolysaccaride, Toll-like receptors, T lymphocytes, Certolizumab pegol
Current Medicinal Chemistry
Title: Tumor Necrosis Factor-Alpha Monoclonal Antibodies for Crohns Disease: Tipping the Balance
Volume: 14 Issue: 14
Author(s): Silvio Danese, Nico Pagano, Erika Angelucci, Tommaso Stefanelli, Alessandro Repici, Paolo Omodei, Marco Daperno and Alberto Malesci
Affiliation:
Keywords: Infliximab, TNF receptors, Lipopolysaccaride, Toll-like receptors, T lymphocytes, Certolizumab pegol
Abstract: Crohns disease (CD) is a chronic inflammatory disorder which may involve any part of gastrointestinal tract. Chronic inflammation is primarily due to an immunological imbalance between pro- and anti-inflammatory cytokines, and with a defective apoptosis of lamina propria T cells. Amongst the pro-inflammatory cytokines tumor necrosis factor-α (TNF-α) seems to play a central role in pathogenesis of CD. Over the last years, increasing knowledge on the pathogenesis of CD together with progresses in bio-technology have led to the development of a number of biological agents targeting specific molecules involved in gut inflammation, most importantly TNF-α and its receptors. The aim of this paper is to critically review the rationale and state-of-the art for the use TNF-α inhibitors in the treatment of CD.
Export Options
About this article
Cite this article as:
Danese Silvio, Pagano Nico, Angelucci Erika, Stefanelli Tommaso, Repici Alessandro, Omodei Paolo, Daperno Marco and Malesci Alberto, Tumor Necrosis Factor-Alpha Monoclonal Antibodies for Crohns Disease: Tipping the Balance, Current Medicinal Chemistry 2007; 14 (14) . https://dx.doi.org/10.2174/092986707780831104
DOI https://dx.doi.org/10.2174/092986707780831104 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Methods in Cytotoxicity Testing: A Review
Recent Patents on Materials Science Bone Changes in Patients with Inflammatory Arthritis Treated with Biological Therapies: A Clinical Perspective
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Patent Selections
Recent Patents on Biomarkers Autocrine and Paracrine Secretion of Vascular Endothelial Growth Factor in the Pre-Hypoxic Diabetic Retina
Current Diabetes Reviews Astrocytic Expression of the Immunoreceptor CD300f Protects Hippocampal Neurons from Amyloid-β Oligomer Toxicity In Vitro
Current Alzheimer Research Immunoproteasome in Cancer and Neuropathologies: A New Therapeutic Target?
Current Pharmaceutical Design Multi-Targeted Agents in Cancer Cell Chemosensitization: What We Learnt from Curcumin Thus Far
Recent Patents on Anti-Cancer Drug Discovery Synthetic Methods for the Preparation of Triazepandiones and Review of their Applications
Current Organic Chemistry Inflammation as a Therapeutic Target in Acute Ischemic Stroke Treatment
Current Topics in Medicinal Chemistry Modulation of the Fce Receptor I Signaling by Tyrosine Kinase Inhibitors: Search for Therapeutic Targets of Inflammatory and Allergy Diseases
Current Pharmaceutical Design Synthesis of Novel Heterocyclic Prostaglandin Analogues
Letters in Organic Chemistry Helminth Infections and Cardiovascular Diseases: Toxocara Species is Contributing to the Disease
Current Cardiology Reviews Editorial (Thematic Issue: Switching to Biological Agents in Autoimmune and Autoinflammatory Disorders: Current Targets and Therapy)
Current Medicinal Chemistry Neuroinflammation and Alzheimer's Disease: Implications for Microglial Activation
Current Alzheimer Research Patterns of Self-Medication with Medicinal Plants and Related Adverse Events - A South American Survey
Current Drug Safety Editorial [Hot Topic: Targeting Cell Migration - The Next Generation Blockbusters (Guest Editors: Amanda E.I. Proudfoot, Marie Kosco-Vilbois and Zoe Johnson)]
Current Immunology Reviews (Discontinued) The Role of COX-1 and COX-2 in Alzheimers Disease Pathology and the Therapeutic Potentials of Non-Steroidal Anti-Inflammatory Drugs
Current Drug Targets - CNS & Neurological Disorders Regulatory Role of G Protein-coupled Receptors in Pancreatic Cancer Development and Progression
Current Medicinal Chemistry Patent Selections:
Recent Patents on Regenerative Medicine Modulation of Cellular Response to Anticancer Treatment by Caffeine: Inhibition of Cell Cycle Checkpoints, DNA Repair and More
Current Pharmaceutical Biotechnology